HCM

HUTCHMED (China) Limited - ADR

15.21

USD

HCM Earnings Reports

Positive Surprise Ratio

HCM beat 5 of 5 last estimates.

100%

Next Report

Date of Next Report

Aug 05, 2026

Estimate for Q2 26 (Revenue/ EPS)

Implied change from Q4 25 (Revenue/ EPS)

Implied change from Q2 25 (Revenue/ EPS)

HUTCHMED (China) Limited - ADR earnings per share and revenue

On Mar 17, 2026, HCM reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.

Looking ahead to Q2 26, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Pharvaris N.V. Ordinary Shares

Report Date

Apr 02, 2026 For Q4 25

Estimate

-$0.63

Actual

-$0.72

Surprise

-13.69%

Palvella Therapeutics, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$0.92

Actual

-$1.07

Surprise

-15.20%

Nanobiotix S.A. - ADR

Report Date

Mar 31, 2026 For Q4 25

Estimate

$0.55

Actual

-$0.39

Surprise

-170.16%

Connect Biopharma Holdings Limited Ordinary Shares

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$1.44

Actual

-$1.91

Surprise

-32.66%

Innate Pharma S.A. ADS

Report Date

Apr 01, 2026 For Q1 26

Estimate

-$0.12

Actual

-$0.55

Surprise

-353.80%

MiNK Therapeutics, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$0.83

Actual

-$0.55

Surprise

+33.64%

Cyclerion Therapeutics, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$0.38

Actual

-$0.21

Surprise

+45.82%

Kairos Pharma, Ltd.

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$0.05

Actual

-$0.07

Surprise

-28.68%

Cadrenal Therapeutics, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$1.18

Actual

-$1.43

Surprise

-20.34%

Sunshine Biopharma Inc.

Report Date

Apr 03, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.54

Surprise

-96.08%

FAQ

What were HUTCHMED (China) Limited - ADR's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, HUTCHMED (China) Limited - ADR reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.

How did the market react to HUTCHMED (China) Limited - ADR's Q4 2025 earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is HUTCHMED (China) Limited - ADR expected to report next?

The next earning report is scheduled for Aug 05, 2026.

What are the forecasts for HUTCHMED (China) Limited - ADR's next earnings report?

Based on -- analysts, HUTCHMED (China) Limited - ADR is expected to report EPS of -- and revenue of -- for Q2 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.